Pharmaceutical Company Compliance Risk Management Research

Corporate Compliance management is one of the pillars of business management,which is directly related to the availability of health operations, the availability of long-term vitality of the fierce competition in the market. With the continuous development of the socialist market economy, the business activities are becoming increasingly internationalized and integrated, enterprise product and business development and economic markets are facing an increasingly complex political environment, compliance risk will be a serious threat to the survival of enterprises and development. So how effective corporate compliance risk management, has become the focus of major companies and joint problems. This paper selects "Pharmaceutical companies Compliance Risk Management," the topic, effectively circumvent the traditional compliance management perspective, pharmaceutical companies choose to risk management and compliance combined, is divided into five parts research and exposition.The first chapter is an introduction. This part of the topic of the research background, significance, research methods and technical route and other content were studied, and then elaborated this study need to improve local innovation and article on this basis, that the follow-up study This study lays the foundation.The second chapter is relevant theory and literature review. The first part of the corporate compliance risk theory, corporate compliance risk management theory,business management theory and corporate commercial bribery and other related theories related to this topic to study, and then separately on the basis of relevant literature at home and abroad to form a Summary, that follow-up study of the theoretical basis of the topic.The third chapter X Company Profile and compliance risk management practices,empirical research. The first part of the X pharmaceutical companies with a brief description of the compliance risk management practices X pharmaceutical companies were analyzed, pharmaceutical companies for X compliance riskmanagement empirical research, and then on the basis of a clear X pharmaceutical companies together compliance risk management problems and lead to reason.Chapter X for improvement and optimization of the company’s internal compliance risk management strategy. The first part of the overall design of clear thinking and compliance risk management, and then on the basis of the selection and design of compliance risk management strategy has been studied in combination with X pharmaceutical company compliance risk management situation, put forward specific compliance risk management improvement measures.The fifth chapter is the conclusion and prospect. The first part of this topic clearly stated conclusions, pointing out at this topic in the research process deficiencies exist, and then on the basis of future research related to this topic were discussed.